Cargando…

Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19

Detalles Bibliográficos
Autores principales:	Di Maria, Emilio, Martini, Paolo, Gennarelli, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834538/ https://www.ncbi.nlm.nih.gov/pubmed/33359911 http://dx.doi.org/10.1016/j.phrs.2020.105402

Ejemplares similares

Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402]
por: Di Maria, Emilio, et al.
Publicado: (2021)

Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants
por: Bojkova, Denisa, et al.
Publicado: (2022)

Candidate drugs against SARS-CoV-2 and COVID-19
por: McKee, Dwight L., et al.
Publicado: (2020)

Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants
por: Tu, Bin, et al.
Publicado: (2022)

Multivalent vaccines against new SARS-CoV-2 hybrid variants
por: Ghazvini, Kiarash, et al.
Publicado: (2023)

The study of olfactory dysfunction in SARS-CoV-2 variants
por: Vaira, Luigi A., et al.
Publicado: (2022)

Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?
por: Santos, Igor de Andrade, et al.
Publicado: (2020)

Kink search for muon candidates in the TPC
por: Stimpfl, G
Publicado: (1986)

Breakthrough infection shapes humoral immunity against SARS-CoV-2 Omicron Variant
por: Zhang, Yuwei, et al.
Publicado: (2023)

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
por: Jeon, Sangeun, et al.
Publicado: (2020)

Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
por: Zhang, Na-Na, et al.
Publicado: (2022)

5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
por: Ngwe Tun, Mya Myat, et al.
Publicado: (2022)

Identification of vaccine candidate against Omicron variant of SARS-CoV-2 using immunoinformatic approaches
por: Aasim, et al.
Publicado: (2022)

Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates
por: Bojkova, Denisa, et al.
Publicado: (2022)

Computational screening for potential drug candidates against the SARS-CoV-2 main protease
por: Silva Andrade, Bruno, et al.
Publicado: (2020)

Omicron variant in the current SARS-CoV-2 pandemic
por: Nasiri, Kaveh, et al.
Publicado: (2022)

SARS-CoV-2 variant-dependent inflammasome activation
por: Teyssou, Elisa, et al.
Publicado: (2023)

Determinants of reinfection with SARS-CoV-2 Omicron variant
por: Bisharat, N., et al.
Publicado: (2023)

Assessment of the Analytical Sensitivity of 10 Lateral Flow Devices against the SARS-CoV-2 Omicron Variant
por: Deerain, Joshua, et al.
Publicado: (2022)

Correlation of vaccine‐elicited antibody levels and neutralizing activities against SARS‐CoV‐2 and its variants
por: Liu, Jinbiao, et al.
Publicado: (2021)

Myeloperoxidase-mediated solution demonstrates rapid virucidal properties against the delta variant of SARS-CoV-2
por: Denys, G.A., et al.
Publicado: (2022)

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
por: Xia, Shuai, et al.
Publicado: (2022)

SARS-CoV-2 seroprevalence in the Vatican City State
por: Ralli, Massimo, et al.
Publicado: (2021)

Sars-Cov-2 and risk of antiviral drug resistance
por: Vitiello, Antonio
Publicado: (2021)

MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters
por: Boudewijns, Robbert, et al.
Publicado: (2022)

Molecular docking studies of Indian variants of pathophysiological proteins of SARS-CoV-2 with selected drug candidates
por: Sridhar, Shruti, et al.
Publicado: (2021)

Different SARS-CoV-2 variants, same prevention strategies
por: Dzinamarira, Tafadzwa, et al.
Publicado: (2021)

High rate of reinfection with the SARS-CoV-2 Omicron variant
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

Mask-off policy in the shadow of emerging variants of SARS-COV-2
por: Shahraki, Abdolrazagh Hashemi, et al.
Publicado: (2021)

Emergence of a new SARS-CoV-2 variant in the UK
por: Tang, Julian W, et al.
Publicado: (2021)

What Is New With Omicron Variant of SARS-CoV-2 in Children?
por: Bittmann, Stefan, et al.
Publicado: (2022)

SARS‐CoV‐2 omicron variant: Could it be another threat?
por: Shanmugaraj, Balamurugan, et al.
Publicado: (2022)

Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern
por: Yadav, Pragya D., et al.
Publicado: (2022)

Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays
por: Ferré, Valentine Marie, et al.
Publicado: (2022)

Surface electrostatic shift on spike protein decreased antibody activities against SARS-CoV-2 Omicron variant
por: Yuan, Shu, et al.
Publicado: (2022)

A novelly designed protein antagonist confers potent neutralization against SARS-CoV-2 variants of concern
por: Lv, Panjing, et al.
Publicado: (2022)

Letter to the Editor in response to the article ‘Candidate drugs against SARS-CoV-2 and COVID-19’
por: Campesi, Ilaria, et al.
Publicado: (2021)

Naturally Available Flavonoid Aglycones as Potential Antiviral Drug Candidates against SARS-CoV-2
por: Al-Karmalawy, Ahmed A., et al.
Publicado: (2021)

Development of DNA Vaccine Candidate against SARS-CoV-2
por: Wang, Xingyun, et al.
Publicado: (2022)

Vaccination of susceptible animals against SARS-CoV-2
por: Xiang, Bin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_65gumt89pim4hqff4eq6avfgf6